Tylenol Stock Recovers Despite Trump Autism Remarks
Tylenol stock rallied Tuesday morning after U.S. President Donald Trump made controversial autism claims linking the drug to vaccines. Shares of Kenvue, Tylenol’s parent company, dropped 7.5% Monday but quickly regained most losses in premarket trading.
The president repeatedly urged pregnant women not to use Tylenol during a White House briefing. He also discouraged mothers from giving infants acetaminophen, the generic name for Tylenol in the U.S. and paracetamol elsewhere.
Kenvue Pushes Back Against Autism Concerns
Kenvue swiftly rejected the claims, stressing there is no proven link between Tylenol and autism. The company warned that avoiding acetaminophen during pregnancy could force mothers into risky alternatives or untreated fevers, both of which pose health dangers.
Kenvue, spun off from Johnson & Johnson in 2023, also makes Band-Aids, Listerine, and several other household staples.
Investors Weigh Lawsuits and Market Risks
Despite Trump’s remarks, analysts see limited risk of fresh lawsuits. Citi’s Filippo Falorni noted that while negative headlines may influence consumer behavior, the lack of new scientific evidence likely cushions Kenvue from long-term damage.
The company has already defended against hundreds of lawsuits alleging ties to autism, with most cases dismissed in court.
Stock Rallies After Sharp Dip
By early Tuesday, shares of Kenvue had rebounded over 7%, signaling investor confidence in the company’s resilience. Falorni added that, without credible new research, markets were likely to stabilize quickly.
Broader Health Debate Continues
Trump’s remarks surfaced alongside Health and Human Services Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” initiative, which highlights potential autism causes. Critics, however, stress the initiative leans on outdated or disputed research.
Stay tuned to Maple Wire for more updates on Tylenol stock performance and the ongoing debate over health policy and consumer trust.
